Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE ; 5(6):400-412, 2022.
Article in English | Web of Science | ID: covidwho-1908094

ABSTRACT

The rampageous transmission of SARS-CoV-2 has been devastatingly impacting human life and public health since late 2019. The waves of pandemic events caused by distinct coronaviruses at present and over the past decades have prompted the need to develop broad-spectrum antiviral drugs against them. In this study, our Pentarlandir ultrapure and potent tannic acids (UPPTA) showed activities against two coronaviral strains, SARSCoV-2 and HCoV-OC43, the earliest-known coronaviruses. The mode of inhibition of Pentarlandir UPPTA is likely to act on 3-chymotrypsin-like protease (3CLpro) to prevent viral replication, as supported by results of biochemical analysis, a 3CLpro assay, and a "gain-of-function" 3CLpro overexpressed cell-based method. Even in the 3CLpro overexpressed environment, Pentarlandir UPPTA remained its antiviral characteristic. Utilizing cell-based virucidal and cytotoxicity assays, the 50% effective concentrations (EC50) and 50% cytotoxicity concentration (CC50) of Pentarlandir UPPTA were determined to be similar to 0.5 and 52.5 mu M against SARS-CoV-2, while they were 1.3 and 205.9 mu M against HCoV-OC43, respectively. In the pharmacokinetic studies, Pentarlandir UPPTA was distributable at a high level to the lung tissue with no accumulation in the body, although the distribution was affected by the food effect. With further investigation in toxicology, Pentarlandir UPPTA demonstrated an overall safe toxicology profile. Taking these findings together, Pentarlandir UPPTA is considered to be a safe and efficacious pancoronal antiviral drug candidate that has been advanced to clinical development.

2.
International Journal of Sustainable Transportation ; 2021.
Article in English | Scopus | ID: covidwho-1104709

ABSTRACT

The last decade witnessed a rapid rise in shared mobility in China. However, there is lack of understanding how the shared mobility market developed, how shared mobility reshapes daily travel patterns, and what shared mobility contributes, if at all, to environmental goals, and in particular climate change mitigation. Here, we systematically review the state of shared mobility in China, scoping 2541 English paper and 12,140 Chinese research papers. We differentiate between ride hailing, car sharing, and bike sharing and analyze the factors shaping shared mobility patterns from the four perspectives of consumers, service providers, the government, and the environment. We also elaborate on governance measures guiding shared mobility and investigate the impact of future shared mobility on a potential low-carbon transportation system transition, highlighting the key role of bike sharing and shared pooled mobility. We show that COVID-19 reduced demand for car hailing, but rendered bike sharing more popular. This work provides a systematic guidance for the future development of shared mobility, and its possibility to contribute to climate change mitigation. © 2021 Taylor & Francis Group, LLC.

3.
Zhonghua Jie He He Hu Xi Za Zhi ; 43(5): 427-430, 2020 May 12.
Article in Chinese | MEDLINE | ID: covidwho-591192

ABSTRACT

Objective: To raise awareness about 2019 novel coronavirus pneumonia (NCP) and reduce missed diagnosis rate and misdiagnosis rate by comparing the clinical characteristics between RNA positive and negative patients clinically diagnosed with NCP. Methods: From January 2020 to February 2020, 54 patients who were newly diagnosed with NCP in Wuhan Fourth Hospital were included in this study. RT-PCR method was used to measure the level of 2019-nCov RNA in pharyngeal swab samples of these patients. The patients were divided into RNA positive and negative group, and the differences of clinical, laboratory, and radiological characteristics were compared. Results: There were 31 RNA of 2019-nCov positive cases, and 23 negative cases. Common clinical symptoms of two groups were fever (80.64% vs. 86.96%) , chills (61.29% vs. 52.17%) , cough (80.64% vs. 95.65%) , fatigue (61.30% vs. 56.52%) , chest distress (77.42% vs.73.91%) . Some other symptoms were headache, myalgia, dyspnea, diarrhea, nausea and vomiting. The laboratory and radiological characteristics of two groups mainly were lymphopenia, increased erythrocyte sedimentation rate, increased C-reactive protein, increased lactate dehydrogenase, decreased oxygenation index, normal white blood cell count and bilateral chest CT involvement. There was no statistically significant difference in other clinical characteristics except for dyspnea between two groups. Conclusions: RNA positive and negative NCP patients shared similar clinical symptoms, while RNA positive NCP patients tended to have dyspnea. Therefore, we should improve the understanding of NCP to prevent missed diagnosis and misdiagnosis; In addition, more rapid and accurate NCP diagnostic approaches should be further developed.


Subject(s)
Coronavirus Infections , Pandemics , Pneumonia, Viral , RNA, Viral , Betacoronavirus/isolation & purification , COVID-19 , COVID-19 Testing , Clinical Laboratory Techniques/standards , Coronavirus Infections/diagnosis , Coronavirus Infections/pathology , Diagnostic Errors/statistics & numerical data , Humans , Missed Diagnosis/statistics & numerical data , Pneumonia, Viral/diagnosis , Pneumonia, Viral/pathology , RNA, Viral/analysis , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL